Bronchial Hyperresponsiveness in Pediatric Non-Cystic Fibrosis Bronchiectasis.

IF 2.4 3区医学 Q1 PEDIATRICS

Pediatric Pulmonology Pub Date : 2026-09-01 DOI:10.1002/ppul.71839

Lisa Gerbeau, Armelle Finet, Margaux Bertrand, Emmanuelle Bosdure, Laura Papazian, Kenza Tahiri, Melisande Baravalle, Julie Mazenq, Jean-Christophe Dubus

{"title":"Bronchial Hyperresponsiveness in Pediatric Non-Cystic Fibrosis Bronchiectasis.","authors":"Lisa Gerbeau, Armelle Finet, Margaux Bertrand, Emmanuelle Bosdure, Laura Papazian, Kenza Tahiri, Melisande Baravalle, Julie Mazenq, Jean-Christophe Dubus","doi":"10.1002/ppul.71839","DOIUrl":null,"url":null,"abstract":"Objective: The prevalence and significance of bronchial hyperresponsiveness (BHR) in patients with non-cystic fibrosis (CF) bronchiectasis remain unclear. The objective is to determine the prevalence of BHR, defined as a post-bronchodilator forced expiratory volume in 1 s (FEV1) improvement > 10%, in children with non-CF bronchiectasis and to assess its association with clinical, functional, and radiological characteristics.Design: This retrospective, observational monocentric study included children with non-CF bronchiectasis followed-up at an university center for rare pediatric respiratory diseases.Patients: Patients were eligible if they had performed spirometry with bronchodilator reversibility testing within 3 years of a diagnostic chest computed tomography (CT).Main outcomes measures: Asthma symptoms, asthma exacerbations, asthma treatments, allergic markers, infectious exacerbations, causes of bronchiectasis, FEV1, FEV1/forced vital capacity (FVC) ratio, reversibility, and mosaic attenuation on CT were compared between patients with and without BHR.Results: Among 157 patients, 65 (male/female sex ratio 0.71, mean age 10 years old, asthma symptoms in over 56% of patients, 67% treated with inhaled corticosteroids) met the inclusion criteria. BHR was present in 32.3% of cases. Patients with BHR had a significantly altered lung function (baseline Z-score FEV1 -2.12 vs -0.87; FEV1/FVC -2.28 vs -0.85). No significant association was found between BHR and clinical and radiological characteristics.Conclusion: BHR is not associated with clinical, radiological or therapeutic characteristics in pediatric non-CF bronchiectasis, except a more severe airflow limitation. These findings highlight the importance of lung function assessment for non-CF bronchiectasis patients.","PeriodicalId":19932,"journal":{"name":"Pediatric Pulmonology","volume":"61 9","pages":"e71839"},"PeriodicalIF":2.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ppul.71839","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The prevalence and significance of bronchial hyperresponsiveness (BHR) in patients with non-cystic fibrosis (CF) bronchiectasis remain unclear. The objective is to determine the prevalence of BHR, defined as a post-bronchodilator forced expiratory volume in 1 s (FEV1) improvement > 10%, in children with non-CF bronchiectasis and to assess its association with clinical, functional, and radiological characteristics.

Design: This retrospective, observational monocentric study included children with non-CF bronchiectasis followed-up at an university center for rare pediatric respiratory diseases.

Patients: Patients were eligible if they had performed spirometry with bronchodilator reversibility testing within 3 years of a diagnostic chest computed tomography (CT).

Main outcomes measures: Asthma symptoms, asthma exacerbations, asthma treatments, allergic markers, infectious exacerbations, causes of bronchiectasis, FEV1, FEV1/forced vital capacity (FVC) ratio, reversibility, and mosaic attenuation on CT were compared between patients with and without BHR.

Results: Among 157 patients, 65 (male/female sex ratio 0.71, mean age 10 years old, asthma symptoms in over 56% of patients, 67% treated with inhaled corticosteroids) met the inclusion criteria. BHR was present in 32.3% of cases. Patients with BHR had a significantly altered lung function (baseline Z-score FEV1 -2.12 vs -0.87; FEV1/FVC -2.28 vs -0.85). No significant association was found between BHR and clinical and radiological characteristics.

Conclusion: BHR is not associated with clinical, radiological or therapeutic characteristics in pediatric non-CF bronchiectasis, except a more severe airflow limitation. These findings highlight the importance of lung function assessment for non-CF bronchiectasis patients.

查看原文本刊更多论文

儿童非囊性纤维化支气管扩张的支气管高反应性。

目的：支气管高反应性（BHR）在非囊性纤维化（CF）支气管扩张患者中的患病率及意义尚不清楚。目的是确定BHR的患病率，定义为支气管扩张剂后1秒用力呼气量（FEV1）改善bbb10 %，在非cf支气管扩张儿童中，并评估其与临床、功能和放射学特征的关系。设计：这项回顾性、观察性单中心研究纳入了在一所大学罕见儿科呼吸系统疾病中心随访的非cf支气管扩张儿童。患者：如果患者在诊断性胸部计算机断层扫描（CT）后3年内进行了肺活量测定和支气管扩张剂可逆性试验，则符合条件。主要结局指标：比较BHR患者和非BHR患者的哮喘症状、哮喘加重、哮喘治疗、过敏标志物、感染性加重、支气管扩张原因、FEV1、FEV1/用力肺活量（FVC）比、可逆性和CT上的mosaic衰减。结果：157例患者中，65例（男女性别比0.71，平均年龄10岁，56%以上患者有哮喘症状，67%接受吸入糖皮质激素治疗）符合纳入标准。32.3%的病例存在BHR。BHR患者的肺功能显著改变（基线z评分FEV1 -2.12 vs -0.87; FEV1/FVC -2.28 vs -0.85）。BHR与临床和放射学特征之间无显著关联。结论：BHR与儿童非cf支气管扩张的临床、放射学或治疗特征无关，除了更严重的气流限制。这些发现强调了肺功能评估对非cf支气管扩张患者的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Pulmonology 医学-呼吸系统

CiteScore

6.00

自引率

12.90%

发文量

468

审稿时长

3-8 weeks

期刊介绍： Pediatric Pulmonology (PPUL) is the foremost global journal studying the respiratory system in disease and in health as it develops from intrauterine life though adolescence to adulthood. Combining explicit and informative analysis of clinical as well as basic scientific research, PPUL provides a look at the many facets of respiratory system disorders in infants and children, ranging from pathological anatomy, developmental issues, and pathophysiology to infectious disease, asthma, cystic fibrosis, and airborne toxins. Focused attention is given to the reporting of diagnostic and therapeutic methods for neonates, preschool children, and adolescents, the enduring effects of childhood respiratory diseases, and newly described infectious diseases. PPUL concentrates on subject matters of crucial interest to specialists preparing for the Pediatric Subspecialty Examinations in the United States and other countries. With its attentive coverage and extensive clinical data, this journal is a principle source for pediatricians in practice and in training and a must have for all pediatric pulmonologists.